Results 221 to 230 of about 1,553,534 (313)

Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Paltusotine is a novel, nonpeptide, selective somatostatin receptor 2 agonist in development for the treatment of acromegaly and carcinoid syndrome. This study investigated the mass balance, routes of excretion, absolute bioavailability and metabolite profile of orally administered paltusotine.
Rosa Luo   +6 more
wiley   +1 more source

Safety of sulfamethoxazole–trimethoprim for the treatment of bacterial infection in outpatient settings: A systematic review and meta‐analysis with active comparator disproportionality analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Sulfamethoxazole–trimethoprim (SMX‐TMP) is a widely used antibiotic for treating bacterial infections, but its safety in adult outpatients remains understudied. This systematic review and meta‐analysis evaluated the safety profile of SMX‐TMP and identified critical research gaps.
Rebecca Preyra   +4 more
wiley   +1 more source

Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza   +26 more
wiley   +1 more source

Hemangioma of glans penis: A case report

open access: yesAsian Journal of Surgery, 2023
Zhenxin Cai   +3 more
doaj  

An open‐label, single‐arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR‐positive, HER2‐negative advanced breast cancer patients: BRIGHT‐1 trial

open access: yesCancer Communications, EarlyView.
Abstract Background Bireociclib (XZP‐3287) is a novel selective cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor, with a favorable safety profile demonstrated in preclinical and phase I studies. BRIGHT‐1 aimed to further explore the efficacy and safety of bireociclib monotherapy in patients with locally advanced, recurrent or metastatic, hormone ...
Jiayu Wang   +18 more
wiley   +1 more source

Bioactive Compound Characterization and Phytopharmacological Potentials of Tulbaghia violacea Fruits and Seeds

open access: yesChemistry &Biodiversity, EarlyView.
Flow chat for the quantitative and qualitative profiles and the biological activities of T. violacea fruits and seeds. ABSTRACT Tulbaghia violacea is an established medicinal plant that is indigenous to southern Africa. All its plant parts have been profiled for their phytochemical constituents and medicinal potentials except for the seeds and fruits ...
Rebecca Opeyemi Oyerinde   +1 more
wiley   +1 more source

Home - About - Disclaimer - Privacy